



Joel M. Gelfand, MD MSCE
Professor of Dermatology and Epidemiology
Vice Chair for Clinical Research and Medical Director, Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
Senior Scholar, Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania Perelman School of Medicine

Joel M. Gelfand is Professor of Dermatology and of Epidemiology (with tenure), Senior Scholar, Center for Clinical Epidemiology and Biostatistics, Vice Chair for Clinical Research and Medical Director of the Clinical Studies Unit in the Department of Dermatology, Founding Director of the Patient Centered Outcomes Research Track in the Masters of Clinical Epidemiology program, Associate Director of the Center for Dermatoepidemiology and Translation, and a Member of the Cancer Center, Center for Pharmacoepidemiology Research and Training, the Penn Institute for Immunology, and the Institute for Translational Medicine and Therapeutics, all at the University of Pennsylvania. He is a board certified dermatologist whose clinical work focuses on general dermatology and psoriasis. He has created a multi-disciplinary approach to the care of psoriasis patients at PENN through his recruitment and mentoring of a rheumatologist and cardiologist who now specialize in systemic complications of psoriasis. His research focuses on clinical trials and epidemiology. His clinical trials research is aimed at improving trial efficiency through the development and validation of surrogate endpoints, the use of efficient statistical designs, and the use of innovative and mechanistic biomarkers. He has designed and conducted clinical trials to evaluate novel therapies for psoriasis, hidradenitis, atopic dermatitis, hair growth, and cutaneous T cell lymphoma.

Dr. Gelfand's epidemiologic research focuses on the natural history of diseases associated with psoriasis and the effectiveness of psoriasis treatments. He has published extensively on the epidemiology of psoriasis and psoriatic arthritis, the impact of psoriasis on health related quality of life, and the risk of various co-morbidities such as obesity, diabetes, hyperlipidemia, lymphoma, renal disease, dementia, major cardiovascular events, and mortality associated with psoriasis. His original research articles have appeared in JAMA, BMJ, Annals of Internal Medicine, Annals of Rheumatic Disease, European Heart Journal, Journal of Investigative Dermatology, JAMA Dermatology, British Journal of Dermatology, and Journal of the American Academy of Dermatology. Many of his research publications have been covered by national and international print (New York Times, Wall Street Journal, Washington Post), internet (CNN, Medscape), and television news media (ABC, CBS, CNN). Dr. Gelfand is the author of over 200 research articles, reviews, and text book chapters which have been cited over 13,000 times (h-index 51 per Google scholar). He is Deputy Editor for the Journal of Investigative Dermatology, a member of the Editorial Board for the Journal of the American Academy of Dermatology and was an associate editor for Pharmacoepidemiology and Drug Safety.

Dr. Gelfand received his undergraduate training at Tufts University, (BS, Biology, Certificate Community Health, *Summa Cum Laude*), and his medical degree from Harvard (



). He performed an internship in internal medicine at Mount Sinai Hospital, (New York, NY), and completed his residency in dermatology at the University of Pennsylvania. He received a Masters of Science in Clinical Epidemiology from the University of Pennsylvania as well. Dr. Gelfand's research and career are supported by grants from the National Institute for Arthritis, Musculoskeletal, and Skin Diseases, the National Heart Lung Blood Institute, the Food and Drug Administration, the American Skin

Association, the National Psoriasis Foundation, and the Dermatology Foundation as well as numerous investigator initiated grants from major pharmaceutical companies. He is the principal investigator for three large ongoing projects: The Dermatology Clinical Effectiveness Research Network (DCERN) which collects data from dermatologists across the US to evaluate effectiveness of psoriasis treatments in real world settings; the Incident Health Outcomes and Psoriasis Events study (iHOPE), a prospective study of 9000 psoriasis patients which evaluates how body surface area of skin involvement influences risk of cardiovascular disease; and, the Vascular Inflammation in Psoriasis trials (VIP) which are rigorous multi-center trials that will determine the impact of psoriasis treatment on novel biomarkers of cardiometabolic disease. He is a member of the American Academy of Dermatology, the Society for Investigative Dermatology and the International Society for Pharmacoepidemiology. He has received numerous awards and honors for his research including: American Skin Association Achievement Award for Psoriasis Research, the Perelman School of Medicine's Marjorie Bowman Award for Clinical Research excellence, election to the American Society for Clinical Investigation and the American Dermatology Association, the Society for Investigative Dermatology's Eugene M Farber lecture, the American Academy of Dermatology's Sulzberger lecture and was the inaugural recipient of the National Psoriasis Foundations award for outstanding scientific achievement.